Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases.
Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration.
The 48-patient Phase 2a INFORM-MS trial in non-active secondary progressive multiple sclerosis completed final participant visits in September 2026. Other clinical programmes investigate foralumab in amyotrophic lateral sclerosis and multiple system atrophy.
Latest News
Tiziana Completes Enrolment in Phase 2 Alzheimer's Trial of Intranasal Foralumab
Tiziana Life Sciences has dosed the last patient in its randomised, placebo-controlled Phase 2 trial of intranasal foralumab in mild Alzheimer's disease, tested alone and alongside lecanemab or donanemab. Topline data are expected in Q1 2027.
Tiziana Doses First Participants in Phase 2a BANYAN ALS Trial
Tiziana Life Sciences has dosed the first three participants in BANYAN, a Phase 2a trial of intranasal foralumab in ALS run within the Healey ALS MyMatch programme at Mass General Brigham. The 44-patient, placebo-controlled study is co-funded by the ALS Association and will assess safety and tolerability alongside biomarkers of regulatory T-cell activity.
Tiziana Completes Last Patient Visit in Phase 2a INFORM-MS Trial
Tiziana Life Sciences has completed the last patient visit in its 48-patient Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The company expects to release 12-week topline data in October.